AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Slightly Bullish +25

VIDEO: Triple therapy regimens being explored for acute myeloid leukemia

📄 This article features a video transcript discussing triple therapy regimens for acute myeloid leukemia (AML).

🧬 A 2016 New England Journal of Medicine paper introduced using genomic information, specifically TP53 mutations, to decide on therapy.

💊 Before the 2016 study, fit patients received "7 + 3" chemotherapy while unfit patients received hypomethylating agents.

📉 The study showed that patients with P53 mutations achieved similar results with hypomethylators as with high-intensity "7 + 3" therapy.

🛑 Consequently, clinicians stopped giving high-intensity "7 + 3" to fit patients with P53 mutations or 17p deletions to avoid side effects.

⚖️ Current frontline standards of care for AML include either high-intensity induction or hypomethylating agents combined with venetoclax (Venclexta).

🔬 Clinical trials are now comparing triple therapy regimens against standard "7 + 3" plus an inhibitor to determine necessary chemo intensity.

💉 Triple therapy combinations may include azacitidine or decitabine, venetoclax, and a targeted agent like an IDH1/2, NPM1, or FLT3 inhibitor.

🏥 Since the drugs are commercially available, clinicians can already implement these triple therapy regimens empirically outside of trials.

🔄 The empirical approach involves giving two drugs first and adding a third agent if the patient's response is suboptimal.

🎯 These concepts aim to explore how much chemotherapy intensity is necessary for patients with targetable mutations.

👨‍⚕️ Noah Merin, MD, PhD, an assistant professor at Cedars-Sinai Medical Center, is the speaker featured in this report.

Bullish Signals
  • Venetoclax (Venclexta), a commercially available drug from AbbVie and Genentech, is now part of competing standards of care for frontline AML treatment.
  • Clinicians can already implement triple therapy regimens empirically using commercially available drugs ahead of clinical trials, allowing for flexible patient-specific treatment approaches.
  • The ability to use genomic information like TP53 mutations to decide on therapy has improved patient outcomes by enabling lower intensity treatments that avoid severe side effects.
  • Emerging targeted agents such as IDH1/2 inhibitors and FLT3 inhibitors offer new options to address specific mutations in AML patients.
  • Minimal residual disease tests are advancing to better match patients with appropriate care, potentially improving treatment efficacy.
Risk Factors
  • The article highlights that the lack of a cure remains the biggest challenge in acute myeloid leukemia (AML).
  • Clinicians are currently exploring triple therapy regimens because existing standards of care may not be sufficient for all patients with targetable mutations.
  • Some patients may require empiric addition of third agents after suboptimal response to two-drug regimens, indicating current therapies may not achieve optimal outcomes initially.
  • The field is still transitioning from high-intensity induction or hypomethylator with venetoclax to new triple therapy combinations, suggesting uncertainty in the optimal treatment landscape.
  • Clinical trials are needed to determine how much chemo intensity is necessary for patients with targetable mutations, implying current data on efficacy is incomplete.
  • Future therapies targeting more common mutations in AML are still hoped for, indicating current options may not cover all patient populations effectively.
Full Analysis
Dr. Noah Merin, an assistant professor of medicine at Cedars-Sinai Medical Center, discusses the evolving treatment landscape for acute myeloid leukemia (AML), highlighting a shift from traditional high-intensity chemotherapy to more targeted approaches based on genomic information. He references a pivotal 2016 study published in The New England Journal of Medicine which demonstrated that patients with TP53 mutations or 17p deletions achieved similar outcomes with hypomethylating agents compared to the standard "7 + 3" high-intensity induction chemotherapy, leading clinicians to adopt lower-intensity therapy for these specific genetic profiles to avoid severe side effects. Consequently, current standards of care now include either high-intensity induction or hypomethylating agents combined with venetoclax (Venclexta), a drug developed by AbbVie and Genentech that is commercially available. The article further explores the emerging exploration of triple therapy regimens in clinical trials, which combine hypomethylating agents like azacitidine or decitabine with venetoclax and targeted inhibitors such as IDH1, IDH2, NPM1, or FLT3 inhibitors. These trials aim to determine the necessary level of chemotherapy intensity for patients with targetable mutations by comparing these triple-drug combinations against 7 + 3 plus an inhibitor. Notably, because the individual components of these regimens are already commercially available, clinicians can empirically implement these combination therapies outside of clinical trials by starting with two drugs and adding a third agent if the patient's response is suboptimal, offering flexibility to fit patient needs while advancing personalized treatment strategies for AML.